Associated Papers
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.
Hiitola E et al.
Science Advances, 2025
Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma.
Geng H et al.
Blood Advances, 2025
High Prevalence of MYD88 and CD79B Mutations in Primary Sinonasal Diffuse Large B-Cell Lymphoma : Identification of an MCD-like Subtype.
Peng F et al.
The American Journal of Surgical Pathology, 2025
Clinical and Genomic Profile of Primary Cranial Neurolymphomatosis.
Wolf EB et al.
Journal of Blood Medicine, 2024
Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets.
Agostinelli C et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2023
Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.
Gao F et al.
Cancer Medicine, 2023
CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
Yamaguchi J et al.
Cancer Medicine, 2023
Case report: Clinicopathological and molecular characteristics of pediatric-type follicular lymphoma.
Ren B et al.
Frontiers in Pediatrics, 2023
Diagnostic value of genetic mutation analysis and mutation profiling of cell-free DNA in intraocular fluid for vitreoretinal lymphoma.
Chen X et al.
Cancer Communications (london, England), 2022
A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas.
Wang X et al.
Haematologica, 2022
IGH Translocations in Chinese Patients With Chronic Lymphocytic Leukemia: Clinicopathologic Characteristics and Genetic Profile.
Li Q et al.
Frontiers in Oncology, 2022
Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
Guan T et al.
Frontiers in Oncology, 2022
Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.
Gao F et al.
Frontiers in Genetics, 2021
Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.
Zhang W et al.
Bmc Cancer, 2020
Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
Chen Z et al.
The American Journal of Surgical Pathology, 2020
Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis.
Suehara Y et al.
Cancer Science, 2019
CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.
Yonese I et al.
European Journal of Haematology, 2019
Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.
Hattori K et al.
Cancer Science, 2019
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA et al.
The Journal of Investigative Dermatology, 2018
Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort.
Bohers E et al.
Blood Cancer Journal, 2018
Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
Zheng M et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2017
Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum.
Greenawalt DM et al.
Oncotarget, 2017
From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.
Jiménez C et al.
Blood Cancer Journal, 2017
Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.
Goetz MP et al.
Journal of the National Cancer Institute, 2017
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
Lionakis MS et al.
Cancer Cell, 2017
MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T et al.
Cancer, 2017
Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.
Alcaide M et al.
Clinical Chemistry, 2016
Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
Yamada S et al.
Leukemia & Lymphoma, 2015
Proteome-wide analysis of human disease mutations in short linear motifs: neglected players in cancer?
Uyar B et al.
Molecular Biosystems, 2014
Mutational analysis of primary central nervous system lymphoma.
Bruno A et al.
Oncotarget, 2014
CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
Kim Y et al.
Human Pathology, 2014
Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
Bohers E et al.
Genes, Chromosomes & Cancer, 2014
EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.
Saieg MA et al.
Cancer Cytopathology, 2013
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Morin RD et al.
Nature, 2011
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE et al.
Nature, 2010